Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP

키워드

참고문헌 (244)

1. Yoon S, "Recommendations for the use of next-generation sequencing and the molecular tumor board for patients with advanced cancer : a report from KSMO and KCSG Precision Medicine Networking Group", Cancer Res Treat, 54, pp.1~9 (2022)
2. Zehir A, "Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients", Nat Med, 23, pp.703~713 (2017)
3. Tsimberidou AM, "Initiative for molecular profiling and advanced cancer therapy(IMPACT) : an MD Anderson precision medicine study", JCO Precis Oncol, 2017, pp.PO.17.00002~ (2017)
4. Massard C, "High-throughput genomics and clinical outcome in hard-to-treat advanced cancers : results of the MOSCATO 01 trial", Cancer Discov, 7, pp.586~595 (2017)
5. Cousin S, "Clinical impact of extensive molecular profiling in advanced cancer patients", J Hematol Oncol, 10, pp.45~ (2017)
6. Tsimberidou AM, "Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson : validation and landmark analyses", Clin Cancer Res, 20, pp.4827~4836 (2014)
7. Andre F, "Genomics to select treatment for patients with metastatic breast cancer", Nature, 610, pp.343~348 (2022)
8. Ettinger DS, "Non-small cell lung cancer, version 3. 2022, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 20, pp.497~530 (2022)
9. Marabelle A, "Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability", mismatch repair-deficient cancer : results from the phase II KEYNOTE-158 study, 2020, pp.38, 1~10
10. Marabelle A, "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study", Lancet Oncol, 21, pp.1353~1365 (2020)
11. Robert C, "Improved overall survival in melanoma with combined dabrafenib and trametinib", N Engl J Med, 372, pp.30~39 (2015)
12. Planchard D, "Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer : an open-label, multicentre phase 2 trial", Lancet Oncol, 17, pp.984~993 (2016)
13. Planchard D, "Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer : an open-label, phase 2 trial", Lancet Oncol, 18, pp.1307~1316 (2017)
14. Subbiah V, "Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer(ROAR) : a phase 2, open-label, single-arm, multicentre basket trial", Lancet Oncol, 21, pp.1234~1243 (2020)
15. Salama AK, "Dabrafenib and trametinib in patients with tumors with BRAF(V600E)mutations : results of the NCI-MATCH trial subprotocol H", J Clin Oncol, 38, pp.3895~3904 (2020)
16. Wen PY, "Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma(ROAR) : a multicentre, open-label, single-arm, phase 2, basket trial", Lancet Oncol, 23, pp.53~64 (2022)
17. Subbiah V, "Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer : updated analysis from the phase II ROAR basket study", Ann Oncol, 33, pp.406~415 (2022)
18. Subbiah V, "Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours(LIBRETTO-001) : a phase 1", 2, open-label, basket trial, 2022, pp.23, 1261~1273
19. Drilon A, "Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children", N Engl J Med, 378, pp.731~739 (2018)
20. Doebele RC, "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours : integrated analysis of three phase 1-2 trials", Lancet Oncol, 21, pp.271~282 (2020)
21. Chakravarty D, "OncoKB : a precision oncology knowledge base", JCO Precis Oncol, 2017, pp.PO.17.00011~ (2017)
22. McConnell L, "A novel next generation sequencing approach to improve sarcoma diagnosis", Mod Pathol, 33, pp.1350~1359 (2020)
23. Szurian K, "Role of next-generation sequencing as a diagnostic tool for the evaluation of bone and soft-tissue tumors", Pathobiology, 84, pp.323~338 (2017)
24. Gounder MM, "Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma", Nat Commun, 13, pp.3406~ (2022)
25. Moch H, "The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A : renal, penile, and testicular tumours", Eur Urol, 82, pp.458~468 (2022)
26. Louis DN, "The 2016 World Health Organization classification of tumors of the central nervous system : a summary", Acta Neuropathol, 131, pp.803~820 (2016)
27. Louis DN, "Announcing cIMPACT-NOW : the consortium to inform molecular and practical approaches to CNS tumor taxonomy", Acta Neuropathol, 133, pp.1~3 (2017)
28. "WHO classification of tumours of the central nervous system tumours" (2021), International Agency for Research on Cancer
29. Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
30. Janne PA, "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer", N Engl J Med, 372, pp.1689~1699 (2015)
31. Westover D, "Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors", Ann Oncol, 29, pp.i10~i19 (2018)
32. Wang Z, "Molecular pathways, resistance mechanisms and targeted interventions in non-smallcell lung cancer", Mol Biomed, 3, pp.42~ (2022)
33. He J, "The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation", Eur J Med Chem, 210, pp.112995~ (2021)
34. Coleman N, "Beyond epidermal growth factor receptor : MET amplification as a general resistance driver to targeted therapy in oncogene-driven nonsmall-cell lung cancer", ESMO Open, 6, pp.100319~ (2021)
35. Soda M, "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", Nature, 448, pp.561~566 (2007)
36. Peters S, "Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer", N Engl J Med, 377, pp.829~838 (2017)
37. Camidge DR, "Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer", N Engl J Med, 379, pp.2027~2039 (2018)
38. Shiba-Ishii A, "Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer", Nat Cancer, 3, pp.710~722 (2022)
39. Yun MR, "Repotrectinib exhibits potent antitumor activity in treatment-naive and solvent-front-mutant ROS1-rearranged non-small cell lung cancer", Clin Cancer Res, 26, pp.3287~3295 (2020)
40. Le DT, "Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instabilityhigh", mismatch repair-deficient metastatic colorectal cancer : KEYNOTE-164, 2020, pp.38, 11~19
41. Mok TS, "Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
42. Rosell R, "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)
43. Wu YL, "Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer(ARCHER 1050) : a randomised, openlabel, phase 3 trial", Lancet Oncol, 18, pp.1454~1466 (2017)
44. Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
45. Cho BC, "A phase 1", 2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors, 2022, pp.17, 558~567
46. Yun CH, "The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP", Proc Natl Acad Sci U S A, 105, pp.2070~2075 (2008)
47. Cross DA, "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer", Cancer Discov, 4, pp.1046~1061 (2014)
48. Zhou C, "Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer : a phase 1", 2 open-label nonrandomized clinical trial, 2021, pp.7, e214761~
49. Park K, "Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy : initial results from the CHRYSALIS phase I study", J Clin Oncol, 39, pp.3391~3402 (2021)
50. Planchard D, "Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer : a single-arm, multicentre, open-label, phase 2 trial", Lancet Oncol, 17, pp.642~650 (2016)
51. Soria JC, "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged nonsmall-cell lung cancer(ASCEND-4) : a randomised, open-label, phase 3 study", Lancet, 389, pp.917~929 (2017)
52. Shaw AT, "First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer", N Engl J Med, 383, pp.2018~2029 (2020)
53. Janne PA, "Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C)mutation", N Engl J Med, 387, pp.120~131 (2022)
54. Skoulidis F, "Sotorasib for lung cancers with KRAS p. G12C mutation", N Engl J Med, 384, pp.2371~2381 (2021)
55. Paik PK, "Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations", N Engl J Med, 383, pp.931~943 (2020)
56. Wolf J, "Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer", N Engl J Med, 383, pp.944~957 (2020)
57. Drilon A, "Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer", N Engl J Med, 383, pp.813~824 (2020)
58. Gainor JF, "Pralsetinib for RET fusion-positive non-small-cell lung cancer(ARROW) : a multi-cohort, open-label, phase 1", 2 study, 2021, pp.22, 959~969
59. Shaw AT, "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer(NSCLC) : updated results, including overall survival, from PROFILE 1001", Ann Oncol, 30, pp.1121~1126 (2019)
60. Drilon A, "Entrectinib in ROS1 fusion-positive non-small-cell lung cancer : integrated analysis of three phase 1-2 trials", Lancet Oncol, 21, pp.261~270 (2020)
61. Mazieres J, "Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced nonsmall-cell lung cancer harboring HER2 mutations : results from the IFCT-1703 R2D2 trial", J Clin Oncol, 40, pp.719~728 (2022)
62. Li BT, "Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer", N Engl J Med, 386, pp.241~251 (2022)
63. Le X, "Poziotinib in non-smallcell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies : ZENITH20-2 trial", J Clin Oncol, 40, pp.710~718 (2022)
64. Iwama E, "Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations", Eur J Cancer, 162, pp.99~106 (2022)
65. Peters S, "Trastuzumab emtansine(TDM1)in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer : efficacy, safety, and biomarkers", Clin Cancer Res, 25, pp.64~72 (2019)
66. Yang G, "Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2alterations : a prospective, open-label, single-arm phase 2 study(PATHER2)", BMC Med, 20, pp.277~ (2022)
67. Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
68. Verma S, "Trastuzumab emtansine for HER2-positive advanced breast cancer", N Engl J Med, 367, pp.1783~1791 (2012)
69. Krop IE, "Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer(TH3RESA) : a randomised, openlabel, phase 3 trial", Lancet Oncol, 15, pp.689~699 (2014)
70. Swain SM, "Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer", N Engl J Med, 372, pp.724~734 (2015)
71. Murthy RK, "Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer", N Engl J Med, 382, pp.597~609 (2020)
72. Hyman DM, "HER kinase inhibition in patients with HER2-and HER3-mutant cancers", Nature, 554, pp.189~194 (2018)
73. Smyth LM, "Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer", Cancer Discov, 10, pp.198~213 (2020)
74. Andre F, "Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer", N Engl J Med, 380, pp.1929~1940 (2019)
75. Rugo HS, "Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4", 6 inhibitor(BYLieve) : one cohort of a phase 2, multicentre, open-label, non-comparative study, 2021, pp.22, 489~498
76. Robson M, "Olaparib for metastatic breast cancer in patients with a germline BRCA mutation", N Engl J Med, 377, pp.523~533 (2017)
77. Litton JK, "Talazoparib in patients with advanced breast cancer and a germline BRCA mutation", N Engl J Med, 379, pp.753~763 (2018)
78. Balasubramaniam S, "FDA approval summary : rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer", Clin Cancer Res, 23, pp.7165~7170 (2017)
79. Tung NM, "TBCRC 048 : phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes", J Clin Oncol, 38, pp.4274~4282 (2020)
80. Gennari A, "ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer", Ann Oncol, 32, pp.1475~1495 (2021)
81. Schmid P, "Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer : the PAKT trial", J Clin Oncol, 38, pp.423~433 (2020)
82. Howell SJ, "Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer(FAKTION) : overall survival, updated progressionfree survival, and expanded biomarker analysis from a randomised, phase 2 trial", Lancet Oncol, 23, pp.851~864 (2022)
83. Bidard FC, "Elacestrant(oral selective estrogen receptor degrader)versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : results from the randomized phase III EMERALD trial", J Clin Oncol, 40, pp.3246~3256 (2022)
84. Hyman DM, "AKT inhibition in solid tumors with AKT1 mutations", J Clin Oncol, 35, pp.2251~2259 (2017)
85. Kuemmel S, "Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant", NPJ Breast Cancer, 6, pp.31~ (2020)
86. Janjigian YY, "First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer : an open-label, single-arm, phase 2 trial", Lancet Oncol, 21, pp.821~831 (2020)
87. Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
88. Shitara K, "Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer", N Engl J Med, 382, pp.2419~2430 (2020)
89. Chung HC, "First-line pembrolizumab", placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer : KEYNOTE-811, 2021, pp.17, 491~501
90. Wainberg ZA, "Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma(FIGHT) : a randomised, double-blind, placebo-controlled, phase 2 study", Lancet Oncol, 23, pp.1430~1440 (2022)
91. Lee J, "Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment : the VIKTORY Umbrella trial", Cancer Discov, 9, pp.1388~1405 (2019)
92. Maron SB, "Epidermal growth factor receptor inhibition in epidermal growth factor receptor-amplified gastroesophageal cancer : retrospective global experience", J Clin Oncol, 40, pp.2458~2467 (2022)
93. Karapetis CS, "K-ras mutations and benefit from cetuximab in advanced colorectal cancer", N Engl J Med, 359, pp.1757~1765 (2008)
94. Van Cutsem E, "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer", N Engl J Med, 360, pp.1408~1417 (2009)
95. Douillard JY, "Panitumumab-FOLFOX4treatment and RAS mutations in colorectal cancer", N Engl J Med, 369, pp.1023~1034 (2013)
96. Van Cutsem E, "Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer", J Clin Oncol, 33, pp.692~700 (2015)
97. Kopetz S, "Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer", N Engl J Med, 381, pp.1632~1643 (2019)
98. Kopetz S, "Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAFmutant metastatic colorectal cancer(SWOG S1406)", J Clin Oncol, 39, pp.285~294 (2021)
99. Overman MJ, "Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient", microsatellite instability-high metastatic colorectal cancer, 2018, pp.36, 773~779
100. Andre T, "Pembrolizumab in microsatellite-instability-high advanced colorectal cancer", N Engl J Med, 383, pp.2207~2218 (2020)
101. Strickler JH, "Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer(MOUNTAINEER) : a multicentre, open-label, phase 2 study", Lancet Oncol, 24, pp.496~508 (2023)
102. Fakih MG, "Sotorasib for previously treated colorectal cancers with KRAS(G12C)mutation(Code-BreaK100) : a prespecified analysis of a single-arm, phase 2 trial", Lancet Oncol, 23, pp.115~124 (2022)
103. Yaeger R, "Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C", N Engl J Med, 388, pp.44~54 (2023)
104. Garmezy B, "Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers", JCO Precis Oncol, 6, pp.e2100267~ (2022)
105. Rousseau B, "PD-1 blockade in solid tumors with defects in polymerase epsilon", Cancer Discov, 12, pp.1435~1448 (2022)
106. Wang F, "Evaluation of POLE and POLD1mutations as biomarkers for immunotherapy outcomes across multiple cancer types", JAMA Oncol, 5, pp.1504~1506 (2019)
107. Ferrarotto R, "A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors", Ann Oncol, 29, pp.1561~1568 (2018)
108. Ferrarotto R, "Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors", J Clin Oncol, 35, pp.352~360 (2017)
109. Jhaveri KL, "Ado-trastuzumab emtansine(T-DM1)in patients with HER2-amplified tumors excluding breast and gastric", gastroesophageal junction(GEJ)adenocarcinomas : results from the NCI-MATCH trial(EAY131)subprotocol Q, 2019, pp.30, 1821~1830
110. Kurzrock R, "Targeted therapy for advanced salivary gland carcinoma based on molecular profiling : results from MyPathway, a phase IIa multiple basket study", Ann Oncol, 31, pp.412~421 (2020)
111. Takahashi H, "Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma", J Clin Oncol, 37, pp.125~134 (2019)
112. Tabernero J, "Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors", J Clin Oncol, 33, pp.3401~3408 (2015)
113. Nogova L, "Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors : results of a global phase I, dose-escalation and dose-expansion study", J Clin Oncol, 35, pp.157~165 (2017)
114. Goke F, "FGFR1 expression levels predict BGJ398 sensitivity of FGFR1-dependent head and neck squamous cell cancers", Clin Cancer Res, 21, pp.4356~4364 (2015)
115. Kochanny SE, "A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent", metastatic head and neck squamous cell carcinoma, 2020, pp.126, 2146~2152
116. Rothenberger NJ, "Hepatocyte growth factor", c-Met signaling in head and neck cancer and implications for treatment, 2017, pp.9, 39~
117. Golan T, "Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer", N Engl J Med, 381, pp.317~327 (2019)
118. Reiss KA, "Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2", J Clin Oncol, 39, pp.2497~2505 (2021)
119. Strickler JH, "Sotorasib in KRAS p. G12C-mutated advanced pancreatic cancer", N Engl J Med, 388, pp.33~43 (2023)
120. Bekaii-Saab TS, "Adagrasib in advanced solid tumors harboring a KRAS(G12C)mutation", J Clin Oncol, 41, pp.4097~4106 (2023)
121. Payne SN, "PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors", Oncogenesis, 4, pp.e169~ (2015)
122. Harder J, "Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer", Br J Cancer, 106, pp.1033~1038 (2012)
123. Singhi AD, "Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma", J Natl Compr Canc Netw, 15, pp.555~562 (2017)
124. Schram AM, "Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions", J Clin Oncol, 39(15 Suppl), pp.3003~ (2021)
125. Pishvaian MJ, "Entrectinib in TRK and ROS1 fusion-positive metastatic pancreatic cancer", JCO Precis Oncol, 2, pp.1~7 (2018)
126. Abou-Alfa GK, "Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma(ClarIDHy) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 study", Lancet Oncol, 21, pp.796~807 (2020)
127. Zhu AX, "Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation : the phase 3 randomized clinical ClarIDHy trial", JAMA Oncol, 7, pp.1669~1677 (2021)
128. Abou-Alfa GK, "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma : a multicentre, open-label, phase 2 study", Lancet Oncol, 21, pp.671~684 (2020)
129. Javle M, "Infigratinib(BGJ398)in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements : mature results from a multicentre, open-label, single-arm, phase 2 study", Lancet Gastroenterol Hepatol, 6, pp.803~815 (2021)
130. Goyal L, "Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma", N Engl J Med, 388, pp.228~239 (2023)
131. Javle M, "Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer(MyPathway) : a multicentre, open-label, phase 2a, multiple basket study", Lancet Oncol, 22, pp.1290~1300 (2021)
132. Lee CK, "Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin : a multi-institutional phase 2 trial of the Korean Cancer Study Group(KCSG-HB19-14)", Lancet Gastroenterol Hepatol, 8, pp.56~65 (2023)
133. Ohba A, "Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer : HERB trial", Future Oncol, 18, pp.2351~2360 (2022)
134. Fader AN, "Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2", neu, 2018, pp.36, 2044~2051
135. Oaknin A, "Endometrial cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up", Ann Oncol, 33, pp.860~877 (2022)
136. Leon-Castillo A, "Interpretation of somatic POLE mutations in endometrial carcinoma", J Pathol, 250, pp.323~335 (2020)
137. Rios-Doria E, "Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma", Gynecol Oncol, 174, pp.262~272 (2023)
138. Talhouk A, "A clinically applicable molecular-based classification for endometrial cancers", Br J Cancer, 113, pp.299~310 (2015)
139. Leon-Castillo A, "Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer : impact on prognosis and benefit from adjuvant therapy", J Clin Oncol, 38, pp.3388~3397 (2020)
140. Kommoss S, "Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series", Ann Oncol, 29, pp.1180~1188 (2018)
141. van den Heerik A, "PORTEC-4a : international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer", Int J Gynecol Cancer, 30, pp.2002~2007 (2020)
142. Gonzalez-Martin A, "Niraparib in patients with newly diagnosed advanced ovarian cancer", N Engl J Med, 381, pp.2391~2402 (2019)
143. Coleman RL, "Veliparib with firstline chemotherapy and as maintenance therapy in ovarian cancer", N Engl J Med, 381, pp.2403~2415 (2019)
144. Mirza MR, "Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer", N Engl J Med, 375, pp.2154~2164 (2016)
145. Moore K, "Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer", N Engl J Med, 379, pp.2495~2505 (2018)
146. Ray-Coquard I, "Olaparib plus bevacizumab as first-line maintenance in ovarian cancer", N Engl J Med, 381, pp.2416~2428 (2019)
147. Ledermann J, "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial", Lancet Oncol, 15, pp.852~861 (2014)
148. Coleman RL, "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy(ARIEL3) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 390, pp.1949~1961 (2017)
149. Pujade-Lauraine E, "Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1", 2 mutation(SOLO2, Lancet Oncol, pp.2017, 18[DOI]
150. Loriot Y, "Erdafitinib in locally advanced or metastatic urothelial carcinoma", N Engl J Med, 381, pp.338~348 (2019)
151. Van Allen EM, "Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma", Cancer Discov, 4, pp.1140~1153 (2014)
152. Liu D, "Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma", JAMA Oncol, 2, pp.1094~1096 (2016)
153. de Bono J, "Olaparib for metastatic castration-resistant prostate cancer", N Engl J Med, 382, pp.2091~2102 (2020)
154. Hussain M, "Survival with olaparib in metastatic castration-resistant prostate cancer", N Engl J Med, 383, pp.2345~2357 (2020)
155. Jonasch E, "Belzutifan for renal cell carcinoma in von Hippel-Lindau disease", N Engl J Med, 385, pp.2036~2046 (2021)
156. Choi Y, "Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma : a multicenter retrospective analysis in Korean patients", Cancer Res Treat, 51, pp.1549~1556 (2019)
157. Srinivasan R, "Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer(HLRCC)or sporadic papillary renal cell cancer", J Clin Oncol, 38(15 Suppl), pp.5004~ (2020)
158. Iannantuono GM, "Activity of ALK inhibitors in renal cancer with ALK alterations : a systematic review", Int J Mol Sci, 23, pp.3995~ (2022)
159. Dummer R, "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma(COLUMBUS) : a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 19, pp.603~615 (2018)
160. Larkin J, "Combined vemurafenib and cobimetinib in BRAF-mutated melanoma", N Engl J Med, 371, pp.1867~1876 (2014)
161. Long GV, "Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma", N Engl J Med, 377, pp.1813~1823 (2017)
162. Long GV, "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma", N Engl J Med, 371, pp.1877~1888 (2014)
163. Gutzmer R, "Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600)mutation-positive melanoma(IMspire150) : primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 395, pp.1835~1844 (2020)
164. Carvajal RD, "KIT as a therapeutic target in metastatic melanoma", JAMA, 305, pp.2327~2334 (2011)
165. Hodi FS, "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin", J Clin Oncol, 31, pp.3182~3190 (2013)
166. Dummer R, "Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma(NEMO) : a multicentre, open-label, randomised, phase 3 trial", Lancet Oncol, 18, pp.435~445 (2017)
167. Shin SJ, "A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors:interim results of dose-escalation and patients with NRASmutant melanoma of dose-expansion", J Clin Oncol, 39(15Suppl), pp.3007~ (2021)
168. Menzies AM, "Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion", Pigment Cell Melanoma Res, 28, pp.607~610 (2015)
169. Hutchinson KE, "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition", Clin Cancer Res, 19, pp.6696~6702 (2013)
170. Bowyer SE, "Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma", Melanoma Res, 24, pp.504~508 (2014)
171. Dankner M, "Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanomas", Clin Cancer Res, 24, pp.6483~6494 (2018)
172. Kim KB, "Phase II study of the MEK1", MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor, 2013, pp.31, 482~489
173. Marconcini R, "Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months", Exp Hematol Oncol, 6, pp.6~ (2017)
174. Demetri GD, "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial", Lancet, 368, pp.1329~1338 (2006)
175. Heinrich MC, "Correlation of longterm results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results : analysis of phase 3SWOG Intergroup Trial S0033", JAMA Oncol, 3, pp.944~952 (2017)
176. Cassier PA, "Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era", Clin Cancer Res, 18, pp.4458~4464 (2012)
177. Heinrich MC, "Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour(NAVIGATOR) : a multicentre, open-label, phase 1 trial", Lancet Oncol, 21, pp.935~946 (2020)
178. McArthur GA, "Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib : Imatinib Target Exploration Consortium Study B2225", J Clin Oncol, 23, pp.866~873 (2005)
179. Navarrete-Dechent C, "Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans : a systematic review", JAMA Dermatol, 155, pp.361~369 (2019)
180. Butrynski JE, "Crizotinib in ALKrearranged inflammatory myofibroblastic tumor", N Engl J Med, 363, pp.1727~1733 (2010)
181. Nishio M, "Phase I study of ceritinib(LDK378)in Japanese patients with advanced, anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors", J Thorac Oncol, 10, pp.1058~1066 (2015)
182. Gettinger SN, "Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies : a single-arm, open-label, phase 1", 2 trial, 2016, pp.17, 1683~1696
183. Gounder M, "Tazemetostat in advanced epithelioid sarcoma with loss of INI1", SMARCB1 : an international, open-label, phase 2 basket study, 2020, pp.21, 1423~1432
184. Tap WD, "Phase I study of the mutant IDH1 inhibitor ivosidenib : safety and clinical activity in patients with advanced chondrosarcoma", J Clin Oncol, 38, pp.1693~1701 (2020)
185. Akumalla S, "Characterization of clinical cases of malignant PEComa via comprehensive genomic profiling of DNA and RNA", Oncology, 98, pp.905~912 (2020)
186. Wagner AJ, "nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors", J Clin Oncol, 39, pp.3660~3670 (2021)
187. Abdul Razak AR, "Co-targeting of MDM2and CDK4", 6 with siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma : results from a proof-of-concept, phase Ib study, 2022, pp.28, 1087~1097
188. LoRusso P, "The MDM2-p53 antagonist brigimadlin(BI 907828)in patients with advanced or metastatic solid tumors : results of a phase Ia, first-in-human, dose-escalation study", Cancer Discov, 13, pp.1802~1813 (2023)
189. Dickson MA, "Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib : a phase 2 clinical trial", JAMA Oncol, 2, pp.937~940 (2016)
190. Schoffski P, "Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations : European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’", Ann Oncol, 28, pp.3000~3008 (2017)
191. Negrini S, "Genomic instability : an evolving hallmark of cancer", Nat Rev Mol Cell Biol, 11, pp.220~228 (2010)
192. Lord CJ, "The DNA damage response and cancer therapy", Nature, 481, pp.287~294 (2012)
193. Yamamoto H, "Homologous recombination deficiencies and hereditary tumors", Int J Mol Sci, 23, pp.348~ (2021)
194. Toh M, "Homologous recombination deficiency : cancer predispositions and treatment implications", Oncologist, 26, pp.e1526~e1537 (2021)
195. Robson ME, "OlympiAD final overall survival and tolerability results : olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer", Ann Oncol, 30, pp.558~566 (2019)
196. Norquist BM, "Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218 : an NRG Oncology", Gynecologic Oncology Group Study, 2018, pp.24, 777~783
197. Pennington KP, "Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas", Clin Cancer Res, 20, pp.764~775 (2014)
198. Geyer CE Jr, "Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1", 2 and high-risk, early breast cancer, 2022, pp.33, 1250~1268
199. Telli ML, "Homologous recombination deficiency(HRD)score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer", Clin Cancer Res, 22, pp.3764~3773 (2016)
200. Watkins JA, "Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers", Breast Cancer Res, 16, pp.211~ (2014)
201. Cancer Genome Atlas Research Network, "Integrated genomic analyses of ovarian carcinoma", Nature, 474, pp.609~615 (2011)
202. Lotan TL, "Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer", Am J Surg Pathol, 44, pp.e15~29 (2020)
203. Sztupinszki Z, "Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer", NPJ Breast Cancer, 4, pp.16~ (2018)
204. Wang X, "HRD-MILN : accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data", Front Genet, 13, pp.990244~ (2022)
205. Lemery S, "First FDA approval agnostic of cancer site : when a biomarker defines the indication", N Engl J Med, 377, pp.1409~1412 (2017)
206. Bonneville R, "Detection of microsatellite instability biomarkers via next-generation sequencing", Methods Mol Biol, 2055, pp.119~132 (2020)
207. Haraldsdottir S, "Microsatellite instability testing using next-generation sequencing data and therapy implications", JCO Precis Oncol, 1, pp.1~4 (2017)
208. Salipante SJ, "Microsatellite instability detection by next generation sequencing", Clin Chem, 60, pp.1192~1199 (2014)
209. Niu B, "MSIsensor : microsatellite instability detection using paired tumor-normal sequence data", Bioinformatics, 30, pp.1015~1016 (2014)
210. Kautto EA, "Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS", Oncotarget, 8, pp.7452~7463 (2017)
211. Hause RJ, "Classification and characterization of microsatellite instability across 18 cancer types", Nat Med, 22, pp.1342~1350 (2016)
212. Kim JE, "Mutation burden and I index for detection of microsatellite instability in colorectal cancer by targeted next-generation sequencing", J Mol Diagn, 21, pp.241~250 (2019)
213. Middha S, "Reliable Pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data", JCO Precis Oncol, 2017, pp.PO.17.00084~ (2017)
214. Sharma P, "The next decade of immune checkpoint therapy", Cancer Discov, 11, pp.838~857 (2021)
215. Patel SP, "PD-L1 expression as a predictive biomarker in cancer immunotherapy", Mol Cancer Ther, 14, pp.847~856 (2015)
216. Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
217. Sha D, "Tumor mutational burden as a predictive biomarker in solid tumors", Cancer Discov, 10, pp.1808~1825 (2020)
218. Samstein RM, "Tumor mutational load predicts survival after immunotherapy across multiple cancer types", Nat Genet, 51, pp.202~206 (2019)
219. Jardim DL, "The challenges of tumor mutational burden as an immunotherapy biomarker", Cancer Cell, 39, pp.154~173 (2021)
220. Marcus L, "FDA approval summary : pembrolizumab for the treatment of tumor mutational burden-high solid tumors", Clin Cancer Res, 27, pp.4685~4689 (2021)
221. Chalmers ZR, "Analysis of 100, 000human cancer genomes reveals the landscape of tumor mutational burden", Genome Med, 9, pp.34~ (2017)
222. Buchhalter I, "Size matters : dissecting key parameters for panel-based tumor mutational burden analysis", Int J Cancer, 144, pp.848~858 (2019)
223. Fumet JD, "Tumour mutational burden as a biomarker for immunotherapy : Current data and emerging concepts", Eur J Cancer, 131, pp.40~50 (2020)
224. Luchini C, "ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1", PD-L1 expression and tumour mutational burden : a systematic review-based approach, 2019, pp.30, 1232~1243
225. Gambardella V, "Personalized medicine : recent progress in cancer therapy", Cancers (Basel), 12, pp.1009~ (2020)
226. Cescon DW, "Circulating tumor DNA and liquid biopsy in oncology", Nat Cancer, 1, pp.276~290 (2020)
227. Sugimoto A, "A large-scale prospective concordance study of plasma-and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer(LC-SCRUM-Liquid)", Clin Cancer Res, 29, pp.1506~1514 (2023)
228. Benayed R, "High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden", Clin Cancer Res, 25, pp.4712~4722 (2019)
229. Heydt C, "Detection of gene fusions using targeted next-generation sequencing : a comparative evaluation", BMC Med Genomics, 14, pp.62~ (2021)
230. Wyatt AW, "Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer", J Natl Cancer Inst, 109, pp.djx118~ (2017)
231. Kingston B, "Genomic profile of advanced breast cancer in circulating tumour DNA", Nat Commun, 12, pp.2423~ (2021)
232. Pascual J, "ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer : a report from the ESMO Precision Medicine Working Group", Ann Oncol, 33, pp.750~768 (2022)
233. Pisapia P, "Liquid biopsy and lung cancer", Acta Cytol, 63, pp.489~496 (2019)
234. Kim H, "Clinical circulating tumor DNA testing for precision oncology", Cancer Res Treat, 55, pp.351~366 (2023)
235. Cha Y, "Utilizing plasma circulating tumor DNA sequencing for precision medicine in the management of solid cancers", Cancer Res Treat, 55, pp.367~384 (2023)
236. Mack PC, "Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer : analysis of over 8000 cases", Cancer, 126, pp.3219~3228 (2020)
237. Leighl NB, "Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer", Clin Cancer Res, 25, pp.4691~4700 (2019)
238. Viller Tuxen I, "Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients", Br J Cancer, 121, pp.125~130 (2019)
239. Mirtavoos-Mahyari H, "Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer", Clin Transl Med, 8, pp.14~ (2019)
240. Zhang Y, "Pan-cancer circulating tumor DNA detection in over 10, 000 Chinese patients", Nat Commun, 12, pp.11~ (2021)
241. Kim S, "Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment", Br J Cancer, 127, pp.898~907 (2022)
242. Cai Z, "Detection of microsatellite instability from circulating tumor DNA by targeted deep sequencing", J Mol Diagn, 22, pp.860~870 (2020)
243. Fridland S, "Assessing tumor heterogeneity : integrating tissue and circulating tumor DNA(ctDNA)analysis in the era of immuno-oncology-blood TMB is not the same as tissue TMB", J Immunother Cancer, 9, pp.e002551~ (2021)
244. Gilson P, "Detection of microsatellite instability : state of the art and future applications in circulating tumour DNA(ctDNA)", Cancers (Basel), 13, pp.1491~ (2021)

관련 논문AI추천